

# Martin G Pomper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/838953/publications.pdf>

Version: 2024-02-01

409  
papers

21,059  
citations

11235

73  
h-index

20023

121  
g-index

429  
all docs

429  
docs citations

429  
times ranked

23946  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Improved <sup>211</sup> At-Labeled Agent for PSMA-Targeted $\beta$ -Therapy. Journal of Nuclear Medicine, 2022, 63, 259-267.	2.8	28
2	First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2022, 63, 536-542.	2.8	56
3	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2022, 63, 248-252.	2.8	13
4	<sup>68</sup> Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1030-1040.	3.3	16
5	Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the <i>AJR</i> Special Series on Imaging of Inflammation. American Journal of Roentgenology, 2022, 218, 940-952.	1.0	5
6	Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT. Cancers, 2022, 14, 270.	1.7	8
7	[ <sup>18</sup> F]DCFPyL PET/CT for Imaging of Prostate Cancer. Nuklearmedizin - NuclearMedicine, 2022, 61, 240-246.	0.3	12
8	Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [ <sup>177</sup> Lu]Lu-PSMA I&T. Cancers, 2022, 14, 647.	1.7	16
9	SPECT and PET Radiotracers in Renal Imaging. Seminars in Nuclear Medicine, 2022, 52, 406-418.	2.5	10
10	A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects. Pharmaceutics, 2022, 14, 373.	2.0	8
11	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup> F-DCFPyL. Molecular Imaging, 2022, 2022, 7056983.	0.7	6
12	A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents. Biomolecules, 2022, 12, 405.	1.8	1
13	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. Molecular Imaging and Biology, 2022, , 1.	1.3	2
14	An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications. Pharmaceutics, 2022, 14, 655.	2.0	4
15	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using <sup>68</sup> Ga-PentixaFor PET. Journal of Nuclear Medicine, 2022, , jnumed.121.263693.	2.8	27
16	<sup>177</sup> Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate, 2022, 82, 826-835.	1.2	20
17	Predictors of <sup>18</sup> F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. Journal of Nuclear Medicine, 2022, 63, 1184-1190.	2.8	12
18	Molecular imaging in oncology: Current impact and future directions. Ca-A Cancer Journal for Clinicians, 2022, 72, 333-352.	157.7	106

#	ARTICLE	IF	CITATIONS
19	Targeted Theranostic <sup>111</sup> In/Lu-Nanotexaphyrin for SPECT Imaging and Photodynamic Therapy. <i>Molecular Pharmaceutics</i> , 2022, 19, 1803-1813.	2.3	9
20	Rechallenge With Additional Doses of <sup>177</sup> Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs. <i>Clinical Nuclear Medicine</i> , 2022, Publish Ahead of Print, .	0.7	2
21	Pifflufolostat F-18 ( <sup>18</sup> F-DCFPyL) for PSMA PET imaging in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 681-694.	1.1	9
22	PET/CT imaging of CSF1R in a mouse model of tuberculosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4088-4096.	3.3	1
23	In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [ <sup>18</sup> F]Me4FDG PET in Rats. <i>Molecular Imaging</i> , 2022, 2022, .	0.7	1
24	System-level optimization in spectroscopic photoacoustic imaging of prostate cancer. <i>Photoacoustics</i> , 2022, 27, 100378.	4.4	10
25	Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 5011-5011.	0.8	2
26	A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 3502-3511.	4.1	28
27	Preclinical evaluation of <sup>213</sup> Bi- <sup>225</sup> Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256388.	2.8	17
28	Triptolide: reflections on two decades of research and prospects for the future. <i>Natural Product Reports</i> , 2021, 38, 843-860.	5.2	70
29	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biological Psychiatry</i> , 2021, 89, e5-e8.	0.7	36
30	<sup>18</sup> F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113047.	2.6	7
31	Subtherapeutic Photodynamic Treatment Facilitates Tumor Nanomedicine Delivery and Overcomes Desmoplasia. <i>Nano Letters</i> , 2021, 21, 344-352.	4.5	28
32	High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 514-520.	2.8	11
33	Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer. <i>Nanoscale</i> , 2021, 13, 9217-9228.	2.8	19
34	Detection of Early Progression with <sup>18</sup> F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1270-1273.	2.8	6
35	Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors. <i>Nanotheranostics</i> , 2021, 5, 182-196.	2.7	12
36	Central Nervous System Molecular Imaging. , 2021, , 1261-1285.		0

#	ARTICLE	IF	CITATIONS
37	A Learned Reconstruction Network for SPECT Imaging. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2021, 5, 26-34.	2.7	20
38	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup> F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	2.8	24
39	First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3122-3128.	3.3	6
40	A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile. <i>Scientific Reports</i> , 2021, 11, 7114.	1.6	20
41	CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. <i>Diagnostics</i> , 2021, 11, 605.	1.3	18
42	Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4059-4070.	2.9	22
43	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [ <sup>111</sup> In]In-XYIMSR-01 for phase I regulatory approval. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 243-250.	0.5	2
44	Synthesis and preliminary evaluation of <sup>211</sup> At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 94-95, 67-80.	0.3	9
45	Imaging <i>Enterobacteriales</i> infections in patients using pathogen-specific positron emission tomography. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
46	Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 665.	1.3	6
47	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 78.	2.4	82
48	Theranostics in Oncology—Thriving, Now More than Ever. <i>Diagnostics</i> , 2021, 11, 805.	1.3	3
49	Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers. <i>Scientific Reports</i> , 2021, 11, 9733.	1.6	9
50	Cellular and Molecular Imaging with SPECT and PET in Brain Tumors. <i>Radiologic Clinics of North America</i> , 2021, 59, 363-375.	0.9	5
51	Narrative review of generative adversarial networks in medical and molecular imaging. <i>Annals of Translational Medicine</i> , 2021, 9, 821-821.	0.7	19
52	Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 30326-30336.	4.0	13
53	A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson's disease. <i>EJNMMI Research</i> , 2021, 11, 52.	1.1	25
54	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 80, 82-94.	0.9	53

#	ARTICLE	IF	CITATIONS
55	Forebrain Shh overexpression improves cognitive function and locomotor hyperactivity in an aneuploid mouse model of Down syndrome and its euploid littermates. <i>Acta Neuropathologica Communications</i> , 2021, 9, 137.	2.4	9
56	CRY <sup>2</sup> B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. <i>Oncogene</i> , 2021, 40, 5752-5763.	2.6	6
57	A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging. <i>Nature Communications</i> , 2021, 12, 5460.	5.8	37
58	Prostate Cancer Theranostics. , 2021, , 1117-1130.		0
59	Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon. <i>Theranostics</i> , 2021, 11, 6105-6119.	4.6	13
60	Measurement of PET Quantitative Bias In Vivo. <i>Journal of Nuclear Medicine</i> , 2021, 62, 732-737.	2.8	3
61	Iterative Fluence Compensation and Spectral Unmixing for Spectroscopic Photoacoustic Imaging. , 2021, , .		2
62	Whole-Body [18F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease. <i>Diagnostics</i> , 2021, 11, 2073.	1.3	3
63	The Number of Frames on ECG-Gated 18F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters. <i>Molecular Imaging</i> , 2021, 2021, 1-8.	0.7	2
64	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Inpatient and Interpatient Variability of Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020, 22, 181-189.	1.3	14
65	Prospective Evaluation of PSMA-Targeted <sup>18</sup> F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 58-61.	2.8	61
66	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020, 22, 190-197.	1.3	27
67	High Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using <sup>18</sup> F-ASEM PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 423-426.	2.8	22
68	Characterizing the Link Between Glial Activation and Changed Functional Connectivity in National Football League Players Using Multimodal Neuroimaging. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 191-195.	0.9	5
69	Preclinical Evaluation of <sup>203</sup> Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 80-88.	2.8	59
70	Prospective Comparison of PET Imaging with PSMA-Targeted <sup>18</sup> F-DCFPyL Versus Na <sup>18</sup> F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 183-188.	2.8	27
71	Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2020, 61, 311-318.	2.8	40
72	$\alpha$ -glucose weighted chemical exchange saturation transfer (glucoCEST)-based dynamic glucose enhanced (DGE) MRI at 3T: early experience in healthy volunteers and brain tumor patients. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 247-262.	1.9	41

#	ARTICLE	IF	CITATIONS
73	Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2020, 17, 98-108.	2.3	14
74	Letter to the Editor re: "Semi-quantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake". <i>Molecular Imaging and Biology</i> , 2020, 22, 19-21.	1.3	0
75	Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 260-268.	0.6	13
76	<sup>18</sup> F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. <i>Theranostics</i> , 2020, 10, 1-16.	4.6	117
77	Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. <i>Journal of Controlled Release</i> , 2020, 317, 312-321.	4.8	35
78	Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent. <i>Photochemistry and Photobiology</i> , 2020, 96, 718-724.	1.3	14
79	The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. <i>Medical Oncology</i> , 2020, 37, 98.	1.2	9
80	T7. UPDATED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS CONFIRMS LOWER LEVELS OF THE GLIAL MARKER TSPO IN PSYCHOSIS PATIENTS. <i>Schizophrenia Bulletin</i> , 2020, 46, S233-S233.	2.3	0
81	Prospective Evaluation of <sup>18</sup> F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. <i>American Journal of Roentgenology</i> , 2020, 215, 652-659.	1.0	22
82	Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [ <sup>124</sup> I]FIAU PET/CT. <i>Molecular Imaging</i> , 2020, 19, 153601212093687.	0.7	11
83	Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2020, 17, 3392-3402.	2.3	20
84	Osteopontin/secreted phosphoprotein-1 behaves as a molecular brake regulating the neuroinflammatory response to chronic viral infection. <i>Journal of Neuroinflammation</i> , 2020, 17, 273.	3.1	14
85	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
86	Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6672.	1.8	3
87	Recent updates and developments in PET imaging of prostate cancer. <i>Abdominal Radiology</i> , 2020, 45, 4063-4072.	1.0	8
88	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENs). <i>BMC Cancer</i> , 2020, 20, 492.	1.1	16
89	cis-4-[18F]fluoro-L-proline Molecular Imaging Experimental Liver Fibrosis. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 90.	1.6	6
90	Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. <i>Theranostics</i> , 2020, 10, 2888-2896.	4.6	28

#	ARTICLE	IF	CITATIONS
91	(S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as a Novel PSMA Targeting Scaffold for Prostate Cancer Imaging. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3563-3576.	2.9	30
92	A physics-guided modular deep-learning based automated framework for tumor segmentation in PET. <i>Physics in Medicine and Biology</i> , 2020, 65, 245032.	1.6	43
93	Novel $^{125}\text{I}$ - and $^{131}\text{I}$ -Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3261-3273.	2.9	7
94	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996.	0.8	107
95	In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [ $^{125}\text{I}$ ]Iodo-ASEM and [ $^{18}\text{F}$ ]ASEM as Radiotracers of Homo- and Heteromeric $^{17}\text{A}$ Nicotinic Acetylcholine Receptors. <i>Molecules</i> , 2020, 25, 1425.	1.7	8
96	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	3.4	696
97	Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating. <i>Translational Andrology and Urology</i> , 2020, 9, 840-842.	0.6	0
98	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on $^{18}\text{F}$ -DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 496-502.	0.2	12
99	PET imaging of soluble epoxide hydrolase in non-human primate brain with [ $^{18}\text{F}$ ]FNDP. <i>EJNMMI Research</i> , 2020, 10, 67.	1.1	10
100	CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9031-9031.	0.8	4
101	Enhancement of Radiotherapy with Human Mesenchymal Stem Cells Containing Gold Nanoparticles. <i>Tomography</i> , 2020, 6, 373-378.	0.8	4
102	Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke. <i>Journal of Nuclear Medicine</i> , 2020, 61, 3-5.	2.8	5
103	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate Cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2020, 38, 116-116.	0.8	1
104	A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia. <i>IScience</i> , 2020, 23, 101536.	1.9	16
105	SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [ $^{125}\text{I}$ ]anti-C3d mAb. <i>Molecular Imaging and Biology</i> , 2019, 21, 473-481.	1.3	19
106	Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data. <i>Journal of Digital Imaging</i> , 2019, 32, 1071-1080.	1.6	5
107	$^{177}\text{Lu}$ -labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2545-2557.	3.3	40
108	Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?. <i>Translational Andrology and Urology</i> , 2019, 8, S263-S264.	0.6	6

#	ARTICLE	IF	CITATIONS
109	CXCR4-Directed Imaging in Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 770.	1.3	47
110	Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. <i>Science Advances</i> , 2019, 5, eaaw5096.	4.7	87
111	Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. <i>Journal of Clinical Medicine</i> , 2019, 8, 1060.	1.0	20
112	Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e443-e451.	5.1	66
113	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019, 79, 1597-1603.	1.2	18
114	[ <sup>68</sup> Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. <i>Frontiers in Oncology</i> , 2019, 9, 503.	1.3	15
115	High-potency ligands for DREADD imaging and activation in rodents and monkeys. <i>Nature Communications</i> , 2019, 10, 4627.	5.8	128
116	Kinetic Control in Assembly of Plasmid DNA/Polycation Complex Nanoparticles. <i>ACS Nano</i> , 2019, 13, 10161-10178.	7.3	35
117	Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. <i>Annual Review of Medicine</i> , 2019, 70, 461-477.	5.0	50
118	Transneuronal Propagation of Pathologic $\alpha$ -Synuclein from the Gut to the Brain Models Parkinson's Disease. <i>Neuron</i> , 2019, 103, 627-641.e7.	3.8	830
119	Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2019, 33, 617-623.	1.2	40
120	PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1940-1951.	3.3	33
121	The next era of renal radionuclide imaging: novel PET radiotracers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1773-1786.	3.3	32
122	Development of [ <sup>18</sup> F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019, 18, 153601211985218.	0.7	52
123	14.3 OPPORTUNITIES IN PRECISION PSYCHIATRY USING PET-BASED NEUROIMAGING. <i>Schizophrenia Bulletin</i> , 2019, 45, S111-S112.	2.3	0
124	23.4 PET-BASED PRECISION NEUROIMAGING OF THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR IN PATIENTS WITH RECENT ONSET OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S127-S127.	2.3	0
125	The effect of ApoE $\mu$ 4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. <i>NeuroImage: Clinical</i> , 2019, 22, 101795.	1.4	34
126	Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 2590-2604.	2.3	29



#	ARTICLE	IF	CITATIONS
127	Association of PET-measured myocardial flow reserve with echocardiography-estimated pulmonary artery systolic pressure in patients with hypertrophic cardiomyopathy. <i>PLoS ONE</i> , 2019, 14, e0212573.	1.1	3
128	Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 255-270.	2.5	81
129	Opportunities in precision psychiatry using PET neuroimaging in psychosis. <i>Neurobiology of Disease</i> , 2019, 131, 104428.	2.1	8
130	Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. <i>Nature Communications</i> , 2019, 10, 1128.	5.8	28
131	MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. <i>Molecular Pharmaceutics</i> , 2019, 16, 2060-2068.	2.3	15
132	Novel Structured Reporting Systems for Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 577-584.	2.8	24
133	The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs. <i>Molecular Imaging and Biology</i> , 2019, 21, 984-990.	1.3	17
134	Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2019, 21, 1054-1063.	1.3	10
135	PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. <i>Urology Case Reports</i> , 2019, 23, 72-74.	0.1	5
136	From the Reading Room to the Courtroom—The Use of Molecular Radionuclide Imaging in Criminal Trials. <i>Journal of the American College of Radiology</i> , 2019, 16, 1612-1617.	0.9	1
137	Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e313-e314.	0.7	3
138	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. <i>Molecular Imaging and Biology</i> , 2019, 21, 567-573.	1.3	46
139	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. <i>Journal of Nuclear Medicine</i> , 2019, 60, 511-516.	2.8	29
140	Use of <sup>18</sup> F-ASEM PET to Determine the Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Recent-Onset Psychosis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 241-243.	2.8	19
141	Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution. <i>Molecular Imaging and Biology</i> , 2019, 21, 790-798.	1.3	10
142	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1686-1691.	3.3	140
143	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561.	3.2	104
144	A Distinct Advantage to Intraarterial Delivery of <sup>89</sup> Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier. <i>Journal of Nuclear Medicine</i> , 2019, 60, 617-622.	2.8	49

#	ARTICLE	IF	CITATIONS
145	Evaluation of <sup>111</sup> In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. <i>Journal of Nuclear Medicine</i> , 2019, 60, 400-406.	2.8	19
146	Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1243-1253.	1.4	8
147	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630.	3.9	94
148	A side-by-side evaluation of [18F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography. <i>Oncotarget</i> , 2019, 10, 5731-5744.	0.8	3
149	Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 416-419.	0.3	3
150	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 424-427.	0.3	2
151	Long-circulating prostate-specific membrane antigen-targeted NIR phototheranostic agent. , 2019, , .		0
152	Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer. <i>Chemistry - A European Journal</i> , 2018, 24, 7235-7242.	1.7	11
153	Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 989-998.	3.3	12
154	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. <i>Biological Psychiatry</i> , 2018, 84, 433-442.	0.7	103
155	Desmin Phosphorylation Triggers Preamyloid Oligomers Formation and Myocyte Dysfunction in Acquired Heart Failure. <i>Circulation Research</i> , 2018, 122, e75-e83.	2.0	46
156	<sup>18</sup> F-XTRA PET for Enhanced Imaging of the Extrathalamic $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1603-1608.	2.8	15
157	Molecularly Targeted MR Imaging Agent in Liver Fibrosis: High Sensitivity and Low Gadolinium Mean High Translational Potential. <i>Radiology</i> , 2018, 287, 590-591.	3.6	4
158	A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18 F-DCFPyL Positron Emission Tomography Imaging. <i>Urology</i> , 2018, 117, 18-21.	0.5	16
159	Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer <i>in vivo</i> . <i>Journal of Biophotonics</i> , 2018, 11, e201800021.	1.1	50
160	Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances. <i>Schizophrenia Research</i> , 2018, 197, 492-497.	1.1	8
161	Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 121, 1081-1089.	0.7	31
162	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 320-332.	2.3	24

#	ARTICLE	IF	CITATIONS
163	Molecular Imaging of Prostate Cancer: Choosing the Right Agent. <i>Journal of Nuclear Medicine</i> , 2018, 59, 787-788.	2.8	4
164	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [ <sup>18</sup> F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. <i>Urology Case Reports</i> , 2018, 17, 22-25.	0.1	7
165	Phenols as Diamagnetic <sup>2</sup> Exchange Magnetic Resonance Imaging Contrast Agents. <i>Chemistry - A European Journal</i> , 2018, 24, 1259-1263.	1.7	13
166	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018, 78, 775-789.	1.2	35
167	Biodistribution and Radiation Dosimetry of <sup>124</sup> I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1751-1756.	2.8	22
168	A Prospective Comparison of <sup>18</sup> F-Sodium Fluoride PET/CT and PSMA-Targeted <sup>18</sup> F-DCFBC PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1665-1671.	2.8	40
169	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1085-1091.	2.8	58
170	Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. <i>Journal of Nuclear Medicine</i> , 2018, 59, 871-877.	2.8	115
171	Low levels of PSMA expression limit the utility of <sup>18</sup> F-DCFPyL PET/CT for imaging urothelial carcinoma. <i>Annals of Nuclear Medicine</i> , 2018, 32, 69-74.	1.2	28
172	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 486-493.	2.8	27
173	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [ <sup>18</sup> F]ASEM. <i>NeuroImage</i> , 2018, 165, 118-124.	2.1	27
174	Changes in [ <sup>18</sup> F]Fluorodeoxyglucose Activities in a Shockwave-Induced Traumatic Brain Injury Model Using Lithotripsy. <i>Journal of Neurotrauma</i> , 2018, 35, 187-194.	1.7	3
175	The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 1-5.	2.1	14
176	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. <i>Journal of Nuclear Medicine</i> , 2018, 59, 479-485.	2.8	122
177	Clinical impact of PSMA-based <sup>18</sup> F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 4-11.	3.3	57
178	Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by <sup>18</sup> F-DCFPyL PET/CT. <i>Urology Case Reports</i> , 2018, 16, 86-88.	0.1	4
179	PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. <i>European Urology</i> , 2018, 73, 485-487.	0.9	108
180	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. <i>Journal of Experimental Medicine</i> , 2018, 215, 159-175.	4.2	121

#	ARTICLE	IF	CITATIONS
181	Prostate Specific Membrane Antigen Targeted <sup>18</sup> F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018, 199, 126-132.	0.2	86
182	Generative Adversarial Networks for the Creation of Realistic Artificial Brain Magnetic Resonance Images. <i>Tomography</i> , 2018, 4, 159-163.	0.8	68
183	Uptake of Prostate-Specific Membrane Antigen-Targeted <sup>18</sup> F-DCFPyL in Cerebral Radionecrosis. <i>Clinical Nuclear Medicine</i> , 2018, 43, e419-e421.	0.7	24
184	The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?. <i>Theranostics</i> , 2018, 8, 6088-6100.	4.6	59
185	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [ <sup>11</sup> C]DPA-713 PET. <i>Journal of Neuroinflammation</i> , 2018, 15, 346.	3.1	46
186	6.1 STUDY OF ALTERED NEUROIMMUNITY IN PSYCHOSIS USING PET-BASED IMAGING OF THE TRANSLOCATOR PROTEIN 18 KDA: PROMISES, PITFALLS, AND FUTURE DIRECTIONS. <i>Schizophrenia Bulletin</i> , 2018, 44, S8-S8.	2.3	0
187	Tuning Pharmacokinetics to Improve Tumor Accumulation of a Prostate-Specific Membrane Antigen-Targeted Phototheranostic Agent. <i>Bioconjugate Chemistry</i> , 2018, 29, 3746-3756.	1.8	26
188	Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on <sup>18</sup> F-DCFPyL PET/CT Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1857-1864.	2.8	43
189	Molecular Imaging of CXCL12 Promoter-driven HSV1-TK Reporter Gene Expression. <i>Biotechnology and Bioprocess Engineering</i> , 2018, 23, 208-217.	1.4	6
190	Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. <i>Nuclear Medicine and Biology</i> , 2018, 62-63, 18-30.	0.3	20
191	Peptide-Based <sup>68</sup> Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 3946-3952.	2.3	102
192	[ <sup>125</sup> I]IodoDPA-713 Binding to 18 kDa Translocator Protein (TSPO) in a Mouse Model of Intracerebral Hemorrhage: Implications for Neuroimaging. <i>Frontiers in Neuroscience</i> , 2018, 12, 66.	1.4	4
193	Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy. <i>Aids</i> , 2018, 32, 1661-1667.	1.0	60
194	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. <i>Annals of Nuclear Medicine</i> , 2018, 32, 512-522.	1.2	37
195	A hyaluronic acid binding peptide-polymer system for treating osteoarthritis. <i>Biomaterials</i> , 2018, 183, 93-101.	5.7	69
196	Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent <sup>90</sup> Y-DOTA-EB-MCG. <i>Bioconjugate Chemistry</i> , 2018, 29, 2309-2315.	1.8	38
197	A comparison of prostate cancer bone metastases on <sup>18</sup> F-Sodium Fluoride and Prostate Specific Membrane Antigen ( <sup>18</sup> F-PSMA) PET/CT: Discordant uptake in the same lesion. <i>Oncotarget</i> , 2018, 9, 37676-37688.	0.8	13
198	PSMA-Targeted <sup>18</sup> F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. <i>European Urology</i> , 2017, 71, 145-146.	0.9	40

#	ARTICLE	IF	CITATIONS
199	Noninvasive Targeted Transcranial Neuromodulation via Focused Ultrasound Gated Drug Release from Nanoemulsions. <i>Nano Letters</i> , 2017, 17, 652-659.	4.5	140
200	Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 157-167.	2.3	41
201	Clinical Experience with <sup>18</sup> F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen. <i>PET Clinics</i> , 2017, 12, 235-241.	1.5	13
202	Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools. <i>Prostate</i> , 2017, 77, 749-764.	1.2	19
203	High Serum Stability of Collagen Hybridizing Peptides and Their Fluorophore Conjugates. <i>Molecular Pharmaceutics</i> , 2017, 14, 1906-1915.	2.3	19
204	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. <i>JAMA Neurology</i> , 2017, 74, 67.	4.5	134
205	Imaging Macrophage Accumulation in a Murine Model of Chronic Pancreatitis with <sup>125</sup> I-Iodo-DPA-713 SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1685-1690.	2.8	12
206	In vivo stem cell tracking with imageable nanoparticles that bind bioorthogonal chemical receptors on the stem cell surface. <i>Biomaterials</i> , 2017, 139, 12-29.	5.7	62
207	Imaging of Prostate-Specific Membrane Antigen Using [ <sup>18</sup> F]DCFPyL. <i>PET Clinics</i> , 2017, 12, 289-296.	1.5	23
208	Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2017, 263, 18-28.	4.8	51
209	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 258-263.	1.0	132
210	Semiquantitative Parameters in PSMA-Targeted PET Imaging with <sup>18</sup> F-DCFPyL: Variability in Normal-Organ Uptake. <i>Journal of Nuclear Medicine</i> , 2017, 58, 942-946.	2.8	38
211	A PSMA-targeted theranostic agent for photodynamic therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 167, 111-116.	1.7	39
212	<sup>111</sup> In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues. <i>Biomacromolecules</i> , 2017, 18, 201-209.	2.6	43
213	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
214	PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells. <i>Journal of Controlled Release</i> , 2017, 267, 163-171.	4.8	21
215	An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted <sup>18</sup> F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e441-e443.	0.7	1
216	Nano-sized metabolic precursors for heterogeneous tumor-targeting strategy using bioorthogonal click chemistry in vivo. <i>Biomaterials</i> , 2017, 148, 1-15.	5.7	51

#	ARTICLE	IF	CITATIONS
217	Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. <i>Nuclear Medicine Communications</i> , 2017, 38, 795-798.	0.5	5
218	Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2017, 42, e433-e435.	0.7	49
219	Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer. <i>BJU International</i> , 2017, 120, 160-161.	1.3	3
220	Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6942-E6951.	3.3	33
221	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2117-2136.	3.3	234
222	18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, 735-740.	0.7	23
223	Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. <i>Science</i> , 2017, 357, 503-507.	6.0	813
224	A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen. <i>Nature Biomedical Engineering</i> , 2017, 1, 977-982.	11.6	58
225	Prostate Cancer Local Recurrence Detected With Both 18 F-Fluciclovine and PSMA-targeted 18 F-DCFPyL PET/CT. <i>Urology</i> , 2017, 107, e9-e10.	0.5	8
226	Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. <i>European Journal of Cancer</i> , 2017, 83, 9-18.	1.3	82
227	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	2.8	165
228	A phase II randomized trial of Observation versus stereotactic ablative Radiation for OLigometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017, 17, 453.	1.1	83
229	Imaging of Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. <i>Molecular Imaging and Biology</i> , 2017, 19, 280-288.	1.3	11
230	Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e65-e68.	0.9	61
231	MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound. <i>Molecular Imaging and Biology</i> , 2017, 19, 24-30.	1.3	15
232	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [ <sup>11</sup> C]DPA-713 positron emission tomography. <i>Lupus</i> , 2017, 26, 170-178.	0.8	25
233	Cardiosphere-Derived Cells Demonstrate Metabolic Flexibility That Is Influenced by Adhesion Status. <i>JACC Basic To Translational Science</i> , 2017, 2, 543-560.	1.9	11
234	Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. <i>PLoS ONE</i> , 2017, 12, e0176958.	1.1	14

#	ARTICLE	IF	CITATIONS
235	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. <i>Annals of Nuclear Medicine</i> , 2017, 31, 696-702.	1.2	34
236	Reproducibility of Cold Uptake Radiomics in 99m Tc-Sestamibi SPECT Imaging of Renal Cell Carcinoma. , 2017, , .		0
237	Chapter 9 Current Landscape of diaCEST Imaging Agents. , 2017, , 159-192.		0
238	Imaging metastatic prostate cancer with 18F-DCFBC PET/CT (DCFBC) and 18F-NaF PET/CT (NaF).. <i>Journal of Clinical Oncology</i> , 2017, 35, 231-231.	0.8	0
239	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5094-TPS5094.	0.8	0
240	A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. <i>Oncotarget</i> , 2016, 7, 12344-12358.	0.8	32
241	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	0.8	158
242	PSMA-targeted imaging of prostate cancer: the best is yet to come. <i>BJU International</i> , 2016, 117, 715-716.	1.3	22
243	Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. <i>Hepatology</i> , 2016, 64, 209-223.	3.6	59
244	Developing imidazoles as CEST MRI pH sensors. <i>Contrast Media and Molecular Imaging</i> , 2016, 11, 304-312.	0.4	47
245	Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2016, 41, 83-85.	0.7	48
246	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	1.3	202
247	Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 208-218.	2.6	15
248	Preclinical Comparative Study of <sup>68</sup> Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. <i>Bioconjugate Chemistry</i> , 2016, 27, 1447-1455.	1.8	54
249	Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1186-1194.	2.4	24
250	Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. <i>Angewandte Chemie</i> , 2016, 128, 12214-12218.	1.6	10
251	Effect of Diffuse Subendocardial Hypoperfusion on Left Ventricular Cavity Size by 13N-Ammonia Perfusion PET in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 1908-1915.	0.7	18
252	Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 90S-96S.	2.8	48

#	ARTICLE	IF	CITATIONS
253	18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1817-1822.	2.8	19
254	An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [ <sup>18</sup> F]DCFPyL. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 439-450.	0.5	59
255	Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2541-2550.	1.9	9
256	PD-L1 Detection in Tumors Using [ <sup>64</sup> Cu]Atezolizumab with PET. <i>Bioconjugate Chemistry</i> , 2016, 27, 2103-2110.	1.8	128
257	Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 12035-12039.	7.2	57
258	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7840-7855.	2.9	47
259	Development of Radiolabeled Ligands Targeting the Glutamate Binding Site of the <i>N</i> -Methyl-D-aspartate Receptor as Potential Imaging Agents for Brain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 11110-11119.	2.9	16
260	Ultrahigh affinity Raman probe for targeted live cell imaging of prostate cancer. <i>Chemical Science</i> , 2016, 7, 6779-6785.	3.7	42
261	Cathepsin...Specific Metabolic Precursor for In...Vivo Tumor-Specific Fluorescence Imaging. <i>Angewandte Chemie</i> , 2016, 128, 14918-14923.	1.6	13
262	ROS-generating TiO <sub>2</sub> nanoparticles for non-invasive sonodynamic therapy of cancer. <i>Scientific Reports</i> , 2016, 6, 23200.	1.6	251
263	Cathepsin...Specific Metabolic Precursor for In...Vivo Tumor-Specific Fluorescence Imaging. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 14698-14703.	7.2	81
264	[ <sup>18</sup> F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. <i>Bioconjugate Chemistry</i> , 2016, 27, 1655-1662.	1.8	15
265	TSPO in a murine model of Sandhoff disease: presymptomatic marker of neurodegeneration and disease pathophysiology. <i>Neurobiology of Disease</i> , 2016, 85, 174-186.	2.1	14
266	(2 <i>S</i> )-2-(3-(1-Carboxy-5-(4- <sup>211</sup> At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted $\beta$ -Particle Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1569-1575.	2.8	101
267	Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. <i>Prostate</i> , 2016, 76, 215-225.	1.2	22
268	PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 18, jew116.	0.5	18
269	PSMA-Based Detection of Prostate Cancer Bone Lesions With 18F-DCFPyL PET/CT: A Sensitive Alternative to 99mTc-MDP Bone Scan and Na <sup>18</sup> F PET/CT?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e115-e118.	0.9	50
270	PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. <i>Biomaterials</i> , 2016, 80, 57-67.	5.7	36



#	ARTICLE	IF	CITATIONS
271	[ <sup>18</sup> F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 206-218.	2.9	37
272	[124I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. <i>Nuclear Medicine and Biology</i> , 2016, 43, 273-279.	0.3	47
273	Critical Length of PEG Grafts on IPEI/DNA Nanoparticles for Efficient in Vivo Delivery. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 567-578.	2.6	43
274	Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. <i>Journal of Nuclear Medicine</i> , 2016, 57, 981-988.	2.8	28
275	Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. <i>Nano Letters</i> , 2016, 16, 2248-2253.	4.5	43
276	Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 106-113.	1.9	27
277	Comparison of Prostate-Specific Membrane Antigen-Based <sup>18</sup> F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	2.8	111
278	[ <sup>64</sup> Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 56471-56479.	0.8	49
279	Study of PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 299-299.	0.8	0
280	Synthesis and Evaluation of Gd <sup>III</sup> -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 10778-10782.	7.2	57
281	In-vivo detection of binary PKA network interactions upon activation of endogenous GPCRs. <i>Scientific Reports</i> , 2015, 5, 11133.	1.6	12
282	Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular $\pi$ -bond shifted hydrogen. <i>Contrast Media and Molecular Imaging</i> , 2015, 10, 74-80.	0.4	28
283	Tumor-specific expression and detection of a CEST reporter gene. <i>Magnetic Resonance in Medicine</i> , 2015, 74, 544-549.	1.9	44
284	Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma Patients. <i>Tomography</i> , 2015, 1, 105-114.	0.8	153
285	Cannabinoid CB2 Receptors in a Mouse Model of A $\beta$ <sup>2</sup> Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. <i>PLoS ONE</i> , 2015, 10, e0129618.	1.1	83
286	Phosphorus-32, a Clinically Available Drug, Inhibits Cancer Growth by Inducing DNA Double-Strand Breakage. <i>PLoS ONE</i> , 2015, 10, e0128152.	1.1	7
287	Multispectral photoacoustic decomposition with localized regularization for detecting targeted contrast agent. <i>Proceedings of SPIE</i> , 2015, , .	0.8	2
288	Structural Characterization and in Vivo Evaluation of <sup>125</sup> I-Hairpin Peptidomimetics as Specific CXCR4 Imaging Agents. <i>Molecular Pharmaceutics</i> , 2015, 12, 941-953.	2.3	13

#	ARTICLE	IF	CITATIONS
289	Evaluation of a PSMA-targeted BNF nanoparticle construct. <i>Nanoscale</i> , 2015, 7, 4432-4442.	2.8	35
290	Molecular imaging of inflammation in the ApoE <sup>-/-</sup> mouse model of atherosclerosis with IodoDPA. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 70-75.	1.0	29
291	[ <sup>125</sup> I]Iodo-ASEM, a specific in vivo radioligand for $\hat{1}\pm 7$ -nAChR. <i>Nuclear Medicine and Biology</i> , 2015, 42, 488-493.	0.3	8
292	Design and assembly of supramolecular dual-modality nanoprobes. <i>Nanoscale</i> , 2015, 7, 9462-9466.	2.8	16
293	Initial Evaluation of [ <sup>18</sup> F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 565-574.	1.3	378
294	Radioiodinated DPA-713 Imaging Correlates with Bactericidal Activity of Tuberculosis Treatments in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 642-649.	1.4	53
295	Preclinical Evaluation of <sup>86</sup> Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. <i>Journal of Nuclear Medicine</i> , 2015, 56, 628-634.	2.8	35
296	Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 771-780.	3.2	53
297	Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2015, 29, 877-882.	1.2	152
298	Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors. <i>Journal of Controlled Release</i> , 2015, 220, 671-681.	4.8	18
299	<sup>18</sup> F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	2.8	180
300	A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression. <i>Cancer Biology and Therapy</i> , 2015, 16, 1764-1774.	1.5	20
301	Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1401-1407.	2.8	90
302	Hyaluronic acid-serum hydrogels rapidly restore metabolism of encapsulated stem cells and promote engraftment. <i>Biomaterials</i> , 2015, 73, 1-11.	5.7	30
303	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. <i>Neurobiology of Disease</i> , 2015, 74, 58-65.	2.1	208
304	Uptake of [ <sup>18</sup> F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies. <i>Tomography</i> , 2015, 1, 81-84.	0.8	31
305	Imaging of carbonic anhydrase IX with an <sup>111</sup> In-labeled dual-motif inhibitor. <i>Oncotarget</i> , 2015, 6, 33733-33742.	0.8	44
306	Tuning Phenols with Intra $\alpha$ -Molecular Bond Shifted Hydrogens (IM $\alpha$ -SHY) as diaCEST MRI Contrast Agents. <i>Chemistry - A European Journal</i> , 2014, 20, 15824-15832.	1.7	43

#	ARTICLE	IF	CITATIONS
307	Human Brain Imaging of $\alpha_7$ nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy. <i>Molecular Imaging and Biology</i> , 2014, 16, 730-738.	1.3	69
308	Imaging Enterobacteriaceae infection in vivo with $^{18}$ F-fluorodeoxyisotripton positron emission tomography. <i>Science Translational Medicine</i> , 2014, 6, 259ra146.	5.8	183
309	Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). <i>Nuclear Medicine and Biology</i> , 2014, 41, 552-561.	0.3	25
310	Sex Differences in Translocator Protein 18 kDa (TSPO) in the Heart: Implications for Imaging Myocardial Inflammation. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 192-202.	1.1	29
311	Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. <i>Journal of NeuroVirology</i> , 2014, 20, 219-232.	1.0	78
312	Structural characterization of P1 $\alpha^2$ -diversified urea-based inhibitors of glutamate carboxypeptidase II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2340-2345.	1.0	14
313	Imaging Axl expression in pancreatic and prostate cancer xenografts. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 635-640.	1.0	9
314	A red-shifted fluorescent substrate for aldehyde dehydrogenase. <i>Nature Communications</i> , 2014, 5, 3662.	5.8	23
315	AEG-1 Promoter-Mediated Imaging of Prostate Cancer. <i>Cancer Research</i> , 2014, 74, 5772-5781.	0.4	33
316	$^{18}$ F-ASEM, a Radiolabeled Antagonist for Imaging the $\alpha_7$ -Nicotinic Acetylcholine Receptor with PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 672-677.	2.8	65
317	Molecular-Genetic Imaging of Cancer. <i>Advances in Cancer Research</i> , 2014, 124, 131-169.	1.9	20
318	$^{64}$ Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2657-2669.	2.9	103
319	Evaluation of Prostate-Specific Membrane Antigen as an Imaging Reporter. <i>Journal of Nuclear Medicine</i> , 2014, 55, 805-811.	2.8	38
320	Heterobivalent Agents Targeting PSMA and Integrin $\alpha_5\beta_3$ . <i>Bioconjugate Chemistry</i> , 2014, 25, 393-405.	1.8	38
321	State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. <i>Journal of Controlled Release</i> , 2014, 187, 133-144.	4.8	434
322	Imaging Denatured Collagen Strands <i>in vivo</i> and <i>Ex vivo</i> via Photo-triggered Hybridization of Caged Collagen Mimetic Peptides. <i>Journal of Visualized Experiments</i> , 2014, , e51052.	0.2	13
323	Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA. <i>Scientific Reports</i> , 2014, 4, 6878.	1.6	118
324	Synthesis and biological evaluation of substrate-based imaging agents for the prostate-specific membrane antigen. <i>Macromolecular Research</i> , 2013, 21, 565-573.	1.0	2

#	ARTICLE	IF	CITATIONS
325	Radiochemical synthesis and in vivo evaluation of [ <sup>18</sup> F]AZ11637326: An agonist probe for the $\alpha_7$ nicotinic acetylcholine receptor. <i>Nuclear Medicine and Biology</i> , 2013, 40, 731-739.	0.3	18
326	Translational Molecular Imaging of Prostate Cancer. <i>Current Radiology Reports</i> , 2013, 1, 216-226.	0.4	14
327	Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 572-575.	0.8	10
328	Clinical applications of Gallium-68. <i>Applied Radiation and Isotopes</i> , 2013, 76, 2-13.	0.7	194
329	Transforming Thymidine into a Magnetic Resonance Imaging Probe for Monitoring Gene Expression. <i>Journal of the American Chemical Society</i> , 2013, 135, 1617-1624.	6.6	80
330	Effect of Chelators on the Pharmacokinetics of <sup>99m</sup> Tc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6108-6121.	2.9	57
331	Noninvasive Molecular Imaging of Tuberculosis-Associated Inflammation With Radioiodinated DPA-713. <i>Journal of Infectious Diseases</i> , 2013, 208, 2067-2074.	1.9	45
332	Salicylic Acid and Analogues as diaCEST MRI Contrast Agents with Highly Shifted Exchangeable Proton Frequencies. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 8116-8119.	7.2	73
333	PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 951-962.	1.0	173
334	Radiation Dosimetry and Biodistribution of the TSPO Ligand <sup>11</sup> C-DPA-713 in Humans. <i>Journal of Nuclear Medicine</i> , 2012, 53, 330-335.	2.8	23
335	Targeting collagen strands by photo-triggered triple-helix hybridization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14767-14772.	3.3	151
336	Biodistribution, Tumor Detection, and Radiation Dosimetry of <sup>18</sup> F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1883-1891.	2.8	264
337	Clinical Translation of Molecular Imaging Probes. , 2012, , 1041-1065.		1
338	Synthesis and Biological Evaluation of Low Molecular Weight Fluorescent Imaging Agents for the Prostate-Specific Membrane Antigen. <i>Bioconjugate Chemistry</i> , 2012, 23, 2377-2385.	1.8	84
339	Cancer imaging: Gene transcription-based imaging and therapeutic systems. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 684-689.	1.2	12
340	PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy. <i>ACS Nano</i> , 2012, 6, 7752-7762.	7.3	95
341	Theranostic imaging of cancer. <i>European Journal of Radiology</i> , 2012, 81, S124-S126.	1.2	16
342	Influence of Bioluminescence Imaging Dynamics by D-Luciferin Uptake and Efflux Mechanisms. <i>Molecular Imaging</i> , 2012, 11, 7290.2012.00005.	0.7	13

#	ARTICLE	IF	CITATIONS
343	Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms. <i>Molecular Imaging</i> , 2012, 11, 499-506.	0.7	7
344	Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7535-7546.	2.9	20
345	A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA). <i>Oncotarget</i> , 2011, 2, 1244-1253.	0.8	53
346	Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. <i>Nature Medicine</i> , 2011, 17, 123-129.	15.2	84
347	The Evolution of Imaging in Cancer: Current State and Future Challenges. <i>Seminars in Oncology</i> , 2011, 38, 3-15.	0.8	79
348	Imaging: CuInSe/ZnS Core/Shell NIR Quantum Dots for Biomedical Imaging (Small 22/2011). <i>Small</i> , 2011, 7, 3106-3106.	5.2	1
349	Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 9167-9170.	7.2	106
350	2-(3-{1-Carboxy-5-[(6-[ <sup>18</sup> F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [ <sup>18</sup> F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7645-7653.	3.2	331
351	Continuing Education Course #1. <i>Toxicologic Pathology</i> , 2011, 39, 267-272.	0.9	6
352	Positron Emission Tomography for Serial Imaging of the Contused Adult Rat Spinal Cord. <i>Molecular Imaging</i> , 2010, 9, 7290.2010.00011.	0.7	8
353	Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection. <i>Journal of NeuroVirology</i> , 2010, 16, 368-376.	1.0	13
354	Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 392-397.	1.0	73
355	Experimental Evaluation of Depth-of-Interaction Correction in a Small-Animal Positron Emission Tomography Scanner. <i>Molecular Imaging</i> , 2010, 9, 7290.2010.00038.	0.7	20
356	Preclinical Evaluation of an <sup>131</sup> I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 4045-4053.	0.4	48
357	Factor Analysis of Proton MR Spectroscopic Imaging Data in HIV Infection: Metabolite-derived Factors Help Identify Infection and Dementia. <i>Radiology</i> , 2010, 254, 577-586.	3.6	36
358	<sup>68</sup> Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5333-5341.	2.9	196
359	Identification of Inhibitors of ABCG2 by a Bioluminescence Imaging-Based High-Throughput Assay. <i>Cancer Research</i> , 2009, 69, 5867-5875.	0.4	44
360	Initial Evaluation of <sup>11</sup> C-DPA-713, a Novel TSPO PET Ligand, in Humans. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1276-1282.	2.8	117

#	ARTICLE	IF	CITATIONS
361	Immunoinaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1124-1130.	2.8	64
362	Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 6932-6940.	0.4	279
363	Serial imaging of human embryonic stem-cell engraftment and teratoma formation in live mouse models. <i>Cell Research</i> , 2009, 19, 370-379.	5.7	52
364	Synthesis of [125I]iodoDPA-713: A new probe for imaging inflammation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 389, 80-83.	1.0	32
365	A low molecular weight PSMA-based fluorescent imaging agent for cancer. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 624-629.	1.0	124
366	Pharmacodynamic Markers for Choline Kinase Down-regulation in Breast Cancer Cells. <i>Neoplasia</i> , 2009, 11, 477-484.	2.3	23
367	Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp. <i>Neoplasia</i> , 2009, 11, 96-101.	2.3	71
368	Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2008, 18, 136-148.	1.0	27
369	Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA). <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4504-4517.	2.9	223
370	Dysregulation of glutamate carboxypeptidase II in psychiatric disease. <i>Schizophrenia Research</i> , 2008, 99, 324-332.	1.1	40
371	Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7737-7743.	2.9	138
372	Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7933-7943.	2.9	180
373	Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). <i>Cancer Biology and Therapy</i> , 2008, 7, 974-982.	1.5	70
374	<i>N</i> -[ <i>N</i> -[( <i>S</i> )-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-L-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3036-3043.	3.2	216
375	Imaging Virus-Associated Cancer. <i>Current Pharmaceutical Design</i> , 2008, 14, 3048-3065.	0.9	3
376	Detection of Dose Response in Chronic Doxorubicin-Mediated Cell Death with Cardiac Technetium 99m Annexin V Single-Photon Emission Computed Tomography. <i>Molecular Imaging</i> , 2008, 7, 7290.2008.00015.	0.7	36
377	Experimental evaluation of the bilinear transformation used in the CT-based attenuation correction for small animal PET imaging. , 2007, , .		1
378	Molecular Neuroimaging: From Conventional to Emerging Techniques. <i>Radiology</i> , 2007, 245, 21-42.	3.6	74

#	ARTICLE	IF	CITATIONS
379	New Techniques for Imaging Human Immunodeficiency Virus-Associated Cognitive Impairment in the Era of Highly Active Antiretroviral Therapy. <i>Archives of Neurology</i> , 2007, 64, 1233.	4.9	3
380	ABCG2/BCRP Expression Modulates $\alpha$ -Luciferin-Based Bioluminescence Imaging. <i>Cancer Research</i> , 2007, 67, 9389-9397.	0.4	80
381	Virus-Associated Tumor Imaging by Induction of Viral Gene Expression. <i>Clinical Cancer Research</i> , 2007, 13, 1453-1458.	3.2	52
382	Imaging of Musculoskeletal Bacterial Infections by $^{124}\text{I}$ FIAU-PET/CT. <i>PLoS ONE</i> , 2007, 2, e1007.	1.1	86
383	In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. <i>Magnetic Resonance in Medicine</i> , 2007, 57, 977-982.	1.9	92
384	Letter to the Editor. <i>Journal of Neuro-Oncology</i> , 2007, 82, 329-329.	1.4	1
385	FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer. <i>Pharmaceutical Research</i> , 2007, 24, 1202-1207.	1.7	18
386	Synthesis of $^{11}\text{C}$ gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 883-888.	0.5	19
387	Imaging glial cell activation with $^{11}\text{C}$ -R-PK11195 in patients with AIDS. <i>Journal of NeuroVirology</i> , 2005, 11, 346-355.	1.0	100
388	NAAG peptidase inhibitors and their potential for diagnosis and therapy. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 1015-1026.	21.5	207
389	A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 21, 325-333.	1.9	51
390	Translational molecular imaging for cancer. <i>Cancer Imaging</i> , 2005, 5, S16-S26.	1.2	42
391	In Vivo Imaging of Peripheral Benzodiazepine Receptors in Mouse Lungs: A Biomarker of Inflammation. <i>Molecular Imaging</i> , 2005, 4, 7290.2005.05133.	0.7	33
392	Potential Applications of Conventional and Molecular Imaging to Biodefense Research. <i>Clinical Infectious Diseases</i> , 2005, 40, 1471-1480.	2.9	17
393	Glutamate carboxypeptidase II levels in rodent brain using $^{125}\text{I}$ DCIT quantitative autoradiography. <i>Neuroscience Letters</i> , 2005, 387, 141-144.	1.0	28
394	Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4022-4028.	3.2	246
395	Small Animal Imaging in Drug Development. <i>Current Pharmaceutical Design</i> , 2005, 11, 3247-3272.	0.9	68
396	Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands. <i>Journal of Nuclear Medicine</i> , 2005, 46, 326-34.	2.8	27

#	ARTICLE	IF	CITATIONS
397	Positron emission tomography in molecular imaging. IEEE Engineering in Medicine and Biology Magazine, 2004, 23, 28-37.	1.1	12
398	Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems. Molecular Imaging and Biology, 2003, 5, 350-362.	1.3	54
399	Tissue Sodium Concentration in Human Brain Tumors as Measured with <sup>23</sup> Na MR Imaging. Radiology, 2003, 227, 529-537.	3.6	268
400	<sup>11</sup> C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase). Molecular Imaging, 2002, 1, 153535002002021.	0.7	27
401	Quantitative MR Spectroscopic Imaging of Brain Lesions in Patients with AIDS. Academic Radiology, 2002, 9, 398-409.	1.3	42
402	Radiosynthesis of [ <sup>11</sup> C]paclitaxel. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 471-477.	0.5	17
403	Can small animal imaging accelerate drug development?. Journal of Cellular Biochemistry, 2002, 87, 211-220.	1.2	24
404	<sup>11</sup> C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase). Molecular Imaging, 2002, 1, 96-101.	0.7	121
405	Molecular Imaging. Academic Radiology, 2001, 8, 1141-1153.	1.3	69
406	11.beta.-Methoxy-, 11.beta.-ethyl, and 17.alpha.-ethynyl-substituted 16.alpha.-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. Journal of Medicinal Chemistry, 1990, 33, 3143-3155.	2.9	128
407	Target tissue uptake selectivity of three fluorine-substituted progestins: Potential imaging agents for receptor-positive breast tumors. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 309-319.	0.3	13
408	<sup>21</sup> [ <sup>18</sup> F]fluoro-16.alpha.-ethyl-19-norprogesterone. Synthesis and target tissue selective uptake of a progestin receptor-based radiotracer for positron emission tomography. Journal of Medicinal Chemistry, 1988, 31, 1360-1363.	2.9	62
409	Molecular imaging: Techniques and current clinical applications. , 0, , 10-21.		8